Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 18/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 18/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 17/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12277622 | 0.89 | SLC6A2 (0.57) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL12235313 | 0.86 | SLC6A2 (0.64) | SLC6A4SLC6A3SLC6A2CYP3A4ALOX15 | |
| SCHEMBL872717 | 0.83 | SLC6A2 (0.80) | SLC6A4SLC6A3SLC6A2CYP3A4ALOX15 | |
| SCHEMBL2274659 | 0.81 | SLC6A4 (0.86) | SLC6A4SLC6A3SLC6A2CYP3A4ALOX15 | |
| SCHEMBL871438 | 0.81 | SLC6A2 (0.68) | SLC6A4SLC6A3SLC6A2CYP3A4ALOX15 | |
| SCHEMBL8167375 | 0.81 | SLC6A4 (0.67) | SLC6A4SLC6A3SLC6A2CYP3A4ALOX15 | |
| SCHEMBL871604 | 0.80 | SLC6A2 (0.64) | SLC6A4SLC6A3SLC6A2CYP3A4ALOX15 | |
| SCHEMBL2278112 | 0.80 | SLC6A4 (0.73) | SLC6A4SLC6A3SLC6A2CYP3A4ALOX15 | |
| Hydrochloric Acid SCHEMBL9117724 | 0.80 | SLC6A4 (0.65) | SLC6A4SLC6A3SLC6A2CYP3A4ALOX15 | |
| SCHEMBL28781360 | 0.79 | SLC6A2 (0.66) | SLC6A4SLC6A3SLC6A2CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066329-B1 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOBUTYLMETHYLAMINES | REVIVA PHARMACEUTICALS INC (US) | 2017-09-06 | — | — | EP | disclosed |
| EP-2066329-B1 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOBUTYLMETHYLAMINES | REVIVA PHARMACEUTICALS INC (US) | 2017-09-06 | — | — | EP | disclosed |
| US-9302981-B2 | Synthesis, methods of using, and compositions of cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-9302981-B2 | Synthesis, methods of using, and compositions of cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-9302981-B2 | Synthesis, methods of using, and compositions of cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20140194508-A1 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOALKYLMETHYLAMINES | REVIVA PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194508-A1 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOALKYLMETHYLAMINES | REVIVA PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194508-A1 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOALKYLMETHYLAMINES | REVIVA PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8669285-B2 | Synthesis, methods of using, and compositions of cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-8669285-B2 | Synthesis, methods of using, and compositions of cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-20110263704-A1 | Methods of Using Cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263704-A1 | Methods of Using Cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263877-A1 | Cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263877-A1 | Cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-7989500-B2 | Synthesis, methods of using, and compositions of cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989500-B2 | Synthesis, methods of using, and compositions of cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989500-B2 | Synthesis, methods of using, and compositions of cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20080139663-A1 | Cycloalkylmethylamine analogs; use treating obesity or related co-morbid indications | REVIVA PHARMACEUTICALS, INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139663-A1 | Cycloalkylmethylamine analogs; use treating obesity or related co-morbid indications | REVIVA PHARMACEUTICALS, INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139663-A1 | Cycloalkylmethylamine analogs; use treating obesity or related co-morbid indications | REVIVA PHARMACEUTICALS, INC. | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263704-A1 | Methods of Using Cycloalkylmethylamines | AADAC, PNMT, INMT | SLC6A4 111/4885SLC6A3 274/4885SLC6A2 465/4885 |
| US-20140194508-A1 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOALKYLMETHYLAMINES | AADAC, INMT, AADAT | SLC6A4 229/4885SLC6A3 541/4885SLC6A2 925/4885 |
| US-20080139663-A1 | Cycloalkylmethylamine analogs; use treating obesity or related co-morbid indications | AADAC, GPR119, MC4R | SLC6A4 108/4885SLC6A3 204/4885SLC6A2 317/4885 |
| US-20110263877-A1 | Cycloalkylmethylamines | AADAC, GPR119, INMT | SLC6A4 126/4885SLC6A3 275/4885SLC6A2 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.